In today’s briefing:
- Kasumigaseki Capital (3498 JP) – An Offering Worth Examining
- Itausa (ITSA4 BZ) – Big NAV Discount Provides Attractive Indirect Exposure to Brazilian Bank Itaú
- EQD | Nikkei 225 WEEKLY Analysis
- Weekly Wrap – 08 Dec 2023
- Interlife General Insurance Company S.a. – 6M-9M FY2023 Results Presentation
Kasumigaseki Capital (3498 JP) – An Offering Worth Examining
- Kasumigaseki Capital is a small cap consulting real estate speculator/developer. They have an interesting, aggressive model. People will recognise the model from pre-GFC but this one is structured better.
- The company had planned explosive growth and in October, brought growth plans forward and guidance way up. Now there is an offering to fund that growth.
- It appears to also be an offering to get a very large short position out of a risk of potential squeeze. For that, I expect this goes smoothly.
Itausa (ITSA4 BZ) – Big NAV Discount Provides Attractive Indirect Exposure to Brazilian Bank Itaú
- Itausa’s equity value is predominantly composed of its core holding stake in big cap Latin American bank Itaú Unibanco whilst it has actively reduced its exposure to wealth tech XP
- Yet these two financials together account for over 90% of Itausa’s total equity value, with Itaú accounting for almost the entirety of that value
- Itausa is trading at a HoldCo NAV discount of over 25%, which is historically high; currently, Itausa is an excellent vehicle that provides indirect and discounted exposure to Itaú
EQD | Nikkei 225 WEEKLY Analysis
- The Nikkei 225 (NKY INDEX) closed the week down (CC=-2) at 32307.86, it’s OVERSOLD, WEEKLY and MONTHLY.
- Our hypothesis is that this pullback is about to end (it could last maybe another week, or maybe it’s already over…), and will be followed by higher prices.
- Go LONG the Nikkei 225 in the support area between 31000 and 32000, this coming week.
Weekly Wrap – 08 Dec 2023
Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.
In this Insight:
and more…
Interlife General Insurance Company S.a. – 6M-9M FY2023 Results Presentation
- Strong Insurance Revenue growth by 11.71% for 2023 (FH 2023: EUR 42,305,397 vs FH 2022: EUR 37,869,728) and robust Investments and Miscellaneous Income growth by 176.62% for 2023 (FH 2023: EUR 12,189,980 vs FH 2022: EUR (15,910,269)) were the key factors for INTERLIFE to return to profitability, posting an EBIT of 13,535,165 EUR, 223.83% increase compared to FY 2022 and an EPS at 0.591 EUR, +221.38% from the FH 2022.
- INTERLIFE holds twice the capital needed for severe disasters, with a Solvency Capital Requirement (SCR=Total eligible own funds / Solvency Capital Requirement) Ratio adequacy of 201.44%, surpassing the 180% Greek benchmark of 2022 and with a Minimum Capital Requirement (MCR= Total eligible own funds / Minimum Capital Requirement) Ratio of 707.87%.
- INTERLIFE does not possess proportional contracts but reinsurance contracts that can reach up to 1 million.